{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T07:32:37Z","timestamp":1649143957802},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.ygyno.2010.05.020","type":"journal-article","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T08:30:30Z","timestamp":1276590630000},"page":"303-307","source":"Crossref","is-referenced-by-count":5,"title":["A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: A feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"118","author":[{"given":"Amy D.","family":"Tiersten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agustin A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Swensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Warshal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula M.","family":"Fracasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.05.020_bib1","series-title":"SEER Cancer Statistics Review, 1975\u20132006","author":"Horner","year":"2009"},{"key":"10.1016\/j.ygyno.2010.05.020_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2009.04.008","article-title":"Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma","volume":"114","author":"Safra","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.05.020_bib3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"Dubois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.05.020_bib4","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B","volume":"90","author":"Budman","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.05.020_bib5","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.1997.15.5.1858","article-title":"Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22","volume":"15","author":"Fisher","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.020_bib6","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.1999.17.11.3374","article-title":"Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25","volume":"17","author":"Fisher","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.020_bib7","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/jnci\/85.21.1732","article-title":"Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis","volume":"85","author":"Levin","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.05.020_bib8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.1995.13.7.1589","article-title":"Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study","volume":"13","author":"McGuire","year":"1995","journal-title":"J Clin Oncol"},{"issue":"4 suppl 10","key":"10.1016\/j.ygyno.2010.05.020_bib9","article-title":"Evolving concepts in the systemic drug therapy of breast cancer","volume":"24","author":"Norton","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.020_bib10","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose-dense vs conventionally scheduled and sequential vs. concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741\/cancer and acute leukemia group B trial 9741","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.020_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjc.6604914","article-title":"Extended weekly dose-dense paclitaxel\/carboplatin is feasible and active in heavily pretreated platinum-resistant recurrent ovarian cancer","volume":"100","author":"Sharma","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2010.05.020_bib12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ygyno.2007.04.003","article-title":"The \u201cLeuven\u201d dose-dense paclitaxel\/carboplatin regimen in patients with recurrent ovarian cancer","volume":"106","author":"Cadron","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.05.020_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/gyno.2002.6859","article-title":"Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer","volume":"88","author":"Havrilesky","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.05.020_bib14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ygyno.2004.03.046","article-title":"A phase II trial of weekly paclitaxel and every 3weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma","volume":"96","author":"Rose","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.05.020_bib15","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2010.05.020_bib16","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.020_bib17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-79-4-604","article-title":"Creatinine clearance: bedside estimate [Letter to the Editor]","volume":"79","author":"Jelliffe","year":"1973","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ygyno.2010.05.020_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.05.020_bib19","unstructured":"Vergote I, Trope C, Amant F, et al. EORTC-GCG\/NCIC-CTG Randomized Trial Comparing Primary Debulking Surgery With Neoadjuvant Chemotherapy In Stage IIIC\u2013IV Ovarian, Fallopian Tube And Peritoneal Cancer (OVCA). International Gynecologic Cancer Society 12th Biennial Meeting 10\/25\/2008."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810004038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810004038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T03:25:24Z","timestamp":1559186724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810004038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0090825810004038"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.05.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}